Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia, Biomedical Research on Medical Devices Human ImmunTracker and Human Immun'IgH (RIPAL)

NCT02520895 COMPLETED

RIPAL is a prospective cohort study, which main goal is to define T and B immune repertoire diversity and magnitude in patients with non-Hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after treatment, and to evaluate the association of these parameters with clinical patient data and outcomes.

Details

Lead sponsor	Hospices Civils de Lyon
Status	COMPLETED
Enrolment	98
Start date	2010-09
Completion	2013-10

Conditions

• LYMPHOMA

Interventions

• blood samplings

Primary outcomes

• change in variations of the T and B cell repertoire in patients with lymphoid blood disease under treatment — from D0 to 18 months
  results given by the technical Immun'IgH® Human and Human ImmunTraCkeR® and score NDL® The 2 criteria for obtaining the data are the diversity and intensity of the immune repertoire: The intensity of the signal corresponds to the frequency of VJ rearrangements detected in the samples. It is expressed in Arbitrary Units. The diversity corresponds to the number of different VJ rearrangements detected compared to all theoretical VJ rearrangement. It is expressed in percentage.

Countries

France